BMJ Best Practice

参考文献

关键文献

Fisher M, Briggs E, Cresswell F, et al. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (PEPSE). 2015. http://www.bashh.org/ (last accessed 25 May 2017).

Centers for Disease Control and Prevention; US Department of Health and Human Services. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV. May 2018 [internet publication].

Ford N, Mayer KH; World Health Organization Postexposure Prophylaxis Guideline Development Group. World Health Organization guidelines on postexposure prophylaxis for HIV: recommendations for a public health approach. Clin Infect Dis. 2015;60(suppl 3):S161-S164.

参考文章

1.  Pinto LA, Landay AL, Berzofsky JA, et al. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Am J Med. 1997;102:21-24.

2.  Spira AI, Marx PA, Patterson BK, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med. 1996;183:215-225.

3.  Fisher M, Briggs E, Cresswell F, et al. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (PEPSE). 2015. http://www.bashh.org/ (last accessed 25 May 2017).

4.  New York State Department of Health AIDS Institute. PEP for occupational exposure to HIV guideline. May 2018 [internet publication].

5.  New York State Department of Health AIDS Institute. PEP for non-occupational exposure to HIV guideline. May 2018 [internet publication].

6.  Centers for Disease Control and Prevention; US Department of Health and Human Services. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV. May 2018 [internet publication].

7.  Department of Health. HIV post-exposure prophylaxis: guidance from the UK Chief Medical Officers' Expert Advisory Group on AIDS. September 2008. http://webarchive.nationalarchives.gov.uk (last accessed 25 May 2017).

8.  Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. October 2016. http://aidsinfo.nih.gov/ (last accessed 25 May 2017).

9.  Greenwald JL, Burstein GR, Pincus J, et al. A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep. 2006,8:125-131.

10.  Schechter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 2004;35:519-525.

11.  Fernández-Balbuena S, Belza M, Castilla J, et al. Awareness and use of nonoccupational HIV post-exposure prophylaxis among people receiving rapid HIV testing in Spain. HIV Med. 2013;14:252-257.

12.  Minas B, Laing S, Jordan H, et al. Improved awareness and appropriate use of non-occupational post-exposure prophylaxis (nPEP) for HIV prevention following a multi-modal communication strategy. BMC Public Health. 2012;12:906.

13.  McCarty EJ, Quah S, Maw R, et al. Post-exposure prophylaxis following sexual exposure to HIV: a seven-year retrospective analysis in a regional centre. Int J STD AIDS. 2011;22:407-408.

14.  Draughon JE, Sheridan DJ. Nonoccupational postexposure prophylaxis for human immunodeficiency virus in Sub-Saharan Africa: a systematic review. J Forensic Nurs. 2011;7:89-96.

15.  Arend E, Maw A, de Swardt C, et al. South African sexual assault survivors' experiences of post-exposure prophylaxis and individualized nursing care: a qualitative study. J Assoc Nurses AIDS Care. 2013;24:154-165.

16.  Health Protection Agency Centre for Infections, National Public Health Service for Wales, CDSC Northern Ireland. Eye of the needle: surveillance of significant occupational exposure to bloodborne viruses in healthcare workers. December 2014. https://www.gov.uk (last accessed 25 May 2017).

17.  World Health Organization. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach. December 2014. http://www.who.int (last accessed 25 May 2017).

18.  Donegan E, Stuart M, Niland JC, et al. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med. 1990;113:733-739.

19.  Mastro TD, de Vincenzi I. Probabilities of sexual HIV-1 transmission. AIDS. 1996;10(Suppl A):S75-S82.

20.  Royce RA, Sena A, Cates W Jr., et al. Sexual transmission of HIV. N Engl J Med. 1997;336:1072-1078. [erratum in: N Engl J Med. 1997;337:799]

21.  de Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. N Engl J Med. 1994;331:341-346.

22.  Anderson RM, May RM. Epidemiological parameters of HIV transmission. Nature. 1988;333:514-519.

23.  Gray R, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357:1149-1153.

24.  Leynaert B, Downs AM, de Vincenzi I; European Study Group on Heterosexual Transmission of HIV. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. Am J Epidemiol. 1998;148:88-96.

25.  Overbaugh J, Sagar M, Benki S, et al. Viral and host factors in HIV-1 transmission and pathogenesis. Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002. Seattle, Washington, DC (abstr. S23).

26.  Vittinghoff E, Douglas J, Judson F, et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol. 1999;150:306-311.

27.  Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr. 1992;5:1116-1118.

28.  Ippolito G, Puro V, De Carli G, et al. The risk of occupational human immunodeficiency virus infection in health care workers. Arch Intern Med. 1993;153:1451-1458.

29.  Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75:3-17.

30.  Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol. 2000;74:9771-9775.

31.  Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998;72:4265-4273.

32.  Le Grand R, Vaslin B, Larghero J, et al. Post-exposure prophylaxis with HAART could not protect macaques from inoculation with SIV/HIV chimera. AIDS. 2000;14:1864-1866.

33.  Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997;337:1485-1490.

34.  Drezett J. Post-exposure prophylaxis in raped women. In: IV International Conference on HIV Infection in Women and Children. Rio de Janeiro: Livro de Resumos. Universidade, Federal do Rio De Janeiro e Institute of Virology of Maryland; 2002.

35.  Centers for Disease Control and Prevention (CDC). Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep. 1995;44:929-933.

36.  Bell DM. Occupational risk of human immunodeficiency virus infection in health care workers: an overview. Am J Med. 1997;102:9-15.

37.  Ganczak M, Barss P, Ganczak M, et al. Nosocomial HIV infection: epidemiology and prevention - a global perspective. AIDS Rev. 2008;10:47-61.

38.  Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institutes of Health, et al. Recommendations for HIV prevention with adults and adolescents with HIV in the United States, 2014. December 2014. http://www.cdc.gov (last accessed 25 May 2017).

39.  Waldo CR, Stall RD, Coates TJ. Is offering post-exposure prevention for sexual exposures to HIV related to sexual risk behavior in gay men? AIDS. 2000;14:1035-1039.

40.  Figueroa JP, Brathwaite A, Morris J, et al. Rising HIV-1 prevalence among sexually transmitted disease clinic attenders in Jamaica: traumatic sex and genital ulcers as risk factors. J Acquir Immune Defic Syndr. 1994;7:310-316.

41.  Landovitz RJ, Fletcher JB, Inzhakova G, et al. A novel combination HIV prevention strategy: post-exposure prophylaxis with contingency management for substance abuse treatment among methamphetamine-using men who have sex with men. AIDS Patient Care STDS. 2012;26:320-328.

42.  Heuker J, Sonder GJ, Stolte I, et al. High HIV incidence among MSM prescribed postexposure prophylaxis, 2000-2009: indications for ongoing sexual risk behaviour. AIDS. 2012;26:505-512.

43.  Llewellyn C, Abraham C, Miners A, et al. Multicentre RCT and economic evaluation of a psychological intervention together with a leaflet to reduce risk behaviour amongst men who have sex with men (MSM) prescribed post-exposure prophylaxis for HIV following sexual exposure (PEPSE): a protocol. BMC Infect Dis. 2012;12:70.

44.  Jain S, Krakower DS, Mayer KH. The transition from postexposure prophylaxis to preexposure prophylaxis: an emerging opportunity for biobehavioral HIV prevention. Clin Infect Dis. 2015;60(suppl 3):S200-S204.

45.  Grant RM, Smith DK. Integrating antiretroviral strategies for human immunodeficiency virus prevention: post- and pre-exposure prophylaxis and early treatment. Open Forum Infect Dis. 2015;2:ofv126.

46.  Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.

47.  Rodger A, et al. HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER study. In: Program and abstracts of the 21st Conference on Retroviruses and Opportunistic Infections, March 3 to 6th, 2014, Boston, U.S., abstract 153LB.

48.  Monitoring the AIDS Pandemic (MAP) Network. The determinants of the HIV/AIDS epidemics in Europe. Geneva, Switzerland: Monitoring the AIDS Pandemic (MAP) Network in conjunction with the 12th World AIDS Conference; 1998.

49.  Merck Frosst Canada Ltd. Isentress (raltegravir) prescribing information. January 2015. https://www.merck.com/ (last accessed 25 May 2017).

50.  ViiV Healthcare ULC. Tivicay (dolutegravir) prescribing information. February 2014. https://www.accessdata.fda.gov (last accessed 25 May 2017).

51.  British national formulary 73. London, UK: British Medical Association and Royal Pharmaceutical Society of Great Britain. BMJ group and RPS Publishing; 2017.

52.  Corey L. Wald A, Celum CL, et al. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr. 2004;35:435-445.

53.  New York State Department of Health AIDS Institute. HIV post-exposure prophylaxis for children beyond the perinatal period. June 2010. http://www.hivguidelines.org/ (last accessed 25 May 2017).

54.  Landovitz RJ, Currier JS. Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med 2009;361:1768-1775.

55.  Mindel A, Tenant-Flowers M. ABC of AIDS: Natural history and management of early HIV infection. BMJ. 2001;322:1290-1293.

56.  Centers for Disease Control and Prevention; US Department of Health and Human Services. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. May 2018 [internet publication].

57.  Department of Health Expert Advisory Group on AIDS. EAGA guidance on HIV post-exposure prophylaxis. April 2015. https://www.gov.uk (last accessed 25 May 2017).

58.  Ford N, Mayer KH; World Health Organization Postexposure Prophylaxis Guideline Development Group. World Health Organization guidelines on postexposure prophylaxis for HIV: recommendations for a public health approach. Clin Infect Dis. 2015;60(suppl 3):S161-S164.

59.  U.S. Department of Health and Human Services. Statement on potential safety signal in infants born to women taking dolutegravir from the HHS antiretroviral guideline panels. May 2018 [internet publication].

60.  Ford N, Shubber Z, Calmy A, et al. Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review. Clin Infect Dis. 2015;60(suppl 3):S170-S176.

61.  Mayer KH, Mimiaga MJ, Gelman M, et al. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr. 2012;59:354-359.

62.  Ford N, Irvine C, Shubber Z, et al. Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis. AIDS. 2014;28:2721-2727.

63.  Blashill AJ, Ehlinger PP, Mayer KH, et al. Optimizing adherence to preexposure and postexposure prophylaxis: the need for an integrated biobehavioral approach. Clin Infect Dis. 2015;60(suppl 3)S187-S190.

64.  Naftalin C, Sikka P, Hill S, et al. Kaletra-based post-exposure prophylaxis (PEP): how does it compare in clinical practice? Sex Transm Inf. 2008;84;e1(D-18).

65.  Tosini W, Muller P, Prazuck T, et al. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation. AIDS. 2010;24:2375-2380.

66.  Wood BR. Nonoccupational postexposure prophylaxis (nPEP) visits: opportunities beyond HIV PEP. Int J Infect Dis. 2015;40:131-132.

使用此内容应接受我们的免责声明。